Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theracos IncfiledCriticalTheracos Inc
Priority to ARP110102051priorityCriticalpatent/AR081882A1/en
Publication of AR081882A1publicationCriticalpatent/AR081882A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se proporcionan formas cristalinas de un compuesto que tiene un efecto inhibitorio sobre el cotransportador de glucosa dependiente de sodio SGLT2. La presente también proporciona composiciones farmacéuticas, métodos para la preparación del compuesto cristalino, y métodos para la utilización del compuesto cristalino, de modo independiente o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o afecciones que se encuentran afectadas por la inhibición de SGLT2 o SGLT.Reivindicación 1: Una forma cristalina del compuesto de fórmula (1).Crystalline forms of a compound are provided that have an inhibitory effect on the sodium dependent glucose transporter SGLT2. This also provides pharmaceutical compositions, methods for the preparation of the crystalline compound, and methods for the use of the crystalline compound, independently or in combination with other therapeutic agents, for the treatment of diseases or conditions that are affected by the inhibition of SGLT2 or SGLT. Claim 1: A crystalline form of the compound of formula (1).
ARP1101020512011-06-132011-06-13
CRYSTALLINE FORM OF INHIBITING BENCILBENCENO OF SGLT2
AR081882A1
(en)
Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925)
Compounds derived from 5-fluoro-2'-deoxyuridine phosphoramidate; preparation procedure; pharmaceutical composition that includes them; its use in the treatment or prophylaxis of cancer.
Composition comprising at least one n-acetyl-lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide; and its use for the prevention and / or treatment of skin conditions and skin diseases.